216 related articles for article (PubMed ID: 10498588)
1. A phase I-II clinical trial to evaluate removal of CD4 cells and partial depletion of CD8 cells from donor marrow for HLA-mismatched unrelated recipients.
Martin PJ; Rowley SD; Anasetti C; Chauncey TR; Gooley T; Petersdorf EW; van Burik JA; Flowers ME; Storb R; Appelbaum FR; Hansen JA
Blood; 1999 Oct; 94(7):2192-9. PubMed ID: 10498588
[TBL] [Abstract][Full Text] [Related]
2. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic bone marrow transplantation with matched unrelated donors for patients with hematologic malignancies using a preparative regimen of high-dose cyclophosphamide and fractionated total body irradiation.
Geller RB; Devine SM; O'Toole K; Persons L; Keller J; Mauer D; Holland HK; Dix SP; Piotti M; Redei I; Connaghan G; Heffner LT; Hillyer CD; Waller EK; Winton EF; Wingard JR
Bone Marrow Transplant; 1997 Aug; 20(3):219-25. PubMed ID: 9257890
[TBL] [Abstract][Full Text] [Related]
4. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
[TBL] [Abstract][Full Text] [Related]
5. Definition of HLA-DQ as a transplantation antigen.
Petersdorf EW; Longton GM; Anasetti C; Mickelson EM; Smith AG; Martin PJ; Hansen JA
Proc Natl Acad Sci U S A; 1996 Dec; 93(26):15358-63. PubMed ID: 8986816
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of pretransplant donor anti-recipient cytotoxic and helper T lymphocyte responses as correlates of acute graft-vs.-host disease and survival after unrelated marrow transplantation.
Pei J; Martin PJ; Longton G; Masewicz S; Mickelson E; Petersdorf E; Anasetti C; Hansen J
Biol Blood Marrow Transplant; 1997 Aug; 3(3):142-9. PubMed ID: 9310191
[TBL] [Abstract][Full Text] [Related]
7. Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: results of a matched-pair analysis.
Barker JN; Davies SM; DeFor T; Ramsay NK; Weisdorf DJ; Wagner JE
Blood; 2001 May; 97(10):2957-61. PubMed ID: 11342417
[TBL] [Abstract][Full Text] [Related]
8. Association of donor-derived host-reactive cytolytic and helper T cells with outcome following alternative donor T cell-depleted bone marrow transplantation.
Keever-Taylor CA; Passweg J; Kawanishi Y; Casper J; Flomenberg N; Baxter-Lowe LA
Bone Marrow Transplant; 1997 May; 19(10):1001-9. PubMed ID: 9169644
[TBL] [Abstract][Full Text] [Related]
9. Marrow transplantation from unrelated donors for patients with severe aplastic anemia who have failed immunosuppressive therapy.
Deeg HJ; Seidel K; Casper J; Anasetti C; Davies S; Gajeweski JL; Territo M; Ramsay N; Harris RE; Catro-Malaspina H; Collins R; Champlin R; Schoch G; King R; Howe C
Biol Blood Marrow Transplant; 1999; 5(4):243-52. PubMed ID: 10465104
[TBL] [Abstract][Full Text] [Related]
10. Role of the mixed lymphocyte culture (MLC) reaction in marrow donor selection: matching for transplants from related haploidentical donors.
Mickelson EM; Guthrie LA; Etzioni R; Anasetti C; Martin PJ; Hansen JA
Tissue Antigens; 1994 Aug; 44(2):83-92. PubMed ID: 7817382
[TBL] [Abstract][Full Text] [Related]
11. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors.
Morishima Y; Sasazuki T; Inoko H; Juji T; Akaza T; Yamamoto K; Ishikawa Y; Kato S; Sao H; Sakamaki H; Kawa K; Hamajima N; Asano S; Kodera Y
Blood; 2002 Jun; 99(11):4200-6. PubMed ID: 12010826
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of tacrolimus and methotrexate for prophylaxis of acute graft-versus-host disease after HLA-A, B, and DRB1 genotypically mismatched unrelated bone marrow transplantation among Japanese patients.
Nishida T; Murayama T; Hirai H; Okamoto S; Sao H; Hara M; Kanamori H; Atsuta Y; Matsuo K; Morishima Y; Kodera Y
Int J Hematol; 2009 Jan; 89(1):98-105. PubMed ID: 19052693
[TBL] [Abstract][Full Text] [Related]
13. Marrow transplant experience for children with severe aplastic anemia.
Sanders JE; Storb R; Anasetti C; Deeg HJ; Doney K; Sullivan KM; Witherspoon RP; Hansen J
Am J Pediatr Hematol Oncol; 1994 Feb; 16(1):43-9. PubMed ID: 8311172
[TBL] [Abstract][Full Text] [Related]
14. Effect of HLA class I or class II incompatibility in pediatric marrow transplantation from unrelated and related donors.
Leung WH; Turner V; Richardson SL; Benaim E; Hale G; Horwitz EM; Woodard P; Bowman LC
Hum Immunol; 2001 Apr; 62(4):399-407. PubMed ID: 11295473
[TBL] [Abstract][Full Text] [Related]
15. Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only condition regimen. Low incidence of failed engraftment and severe acute GVHD.
Topolsky D; Crilley P; Styler MJ; Bulova S; Brodsky I; Marks DI
Bone Marrow Transplant; 1996 Apr; 17(4):549-54. PubMed ID: 8722353
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: major prognostic impact of HLA class I identity between donor and recipient.
Spencer A; Szydlo RM; Brookes PA; Kaminski E; Rule S; van Rhee F; Ward KN; Hale G; Waldmann H; Hows JM; Batchelor JR; Goldman JM
Blood; 1995 Nov; 86(9):3590-7. PubMed ID: 7579468
[TBL] [Abstract][Full Text] [Related]
17. Children with acute lymphoblastic leukemia who receive T-cell-depleted HLA mismatched marrow allografts from unrelated donors have an increased incidence of primary graft failure but a similar overall transplant outcome.
Green A; Clarke E; Hunt L; Canterbury A; Lankester A; Hale G; Waldmann H; Goodman S; Cornish JM; Marks DI; Steward CG; Oakhill A; Pamphilon DH
Blood; 1999 Oct; 94(7):2236-46. PubMed ID: 10498594
[TBL] [Abstract][Full Text] [Related]
18. Low-dose donor CD8+ cells in the CD4-depleted graft prevent allogeneic marrow graft rejection and severe graft-versus-host disease for chronic myeloid leukemia patients in first chronic phase.
Gallardo D; García-López J; Sureda A; Canals C; Ferra C; Cancelas JA; Berlanga JJ; Brunet S; Boqué C; Picón M; Torrico C; Amill B; Martino R; Martínez C; Martín-Henao G; Domingo-Albós A; Grañena A
Bone Marrow Transplant; 1997 Dec; 20(11):945-52. PubMed ID: 9422473
[TBL] [Abstract][Full Text] [Related]
19. The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone.
Nademanee A; Schmidt GM; Parker P; Dagis AC; Stein A; Snyder DS; O'Donnell M; Smith EP; Stepan DE; Molina A
Blood; 1995 Aug; 86(3):1228-34. PubMed ID: 7620176
[TBL] [Abstract][Full Text] [Related]
20. Use of partially mismatched related donors extends access to allogeneic marrow transplant.
Henslee-Downey PJ; Abhyankar SH; Parrish RS; Pati AR; Godder KT; Neglia WJ; Goon-Johnson KS; Geier SS; Lee CG; Gee AP
Blood; 1997 May; 89(10):3864-72. PubMed ID: 9160695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
